Home > Insider Trading > Filing (0001209191-11-013985)

Filing Details

Accession Number:: 0001209191-11-013985
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-03-01 18:57:19
Reporting Period:: 2011-02-25

Filing Date:: 2011-03-01
Accepted Time:: 2011-03-01 18:57:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1113481	Medicines Co	MDCO	Pharmaceutical Preparations (2834)	043324394

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1204787	Clive Meanwell	8 Sylvan Way Parsippany NJ 07054	Chairman & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2011-02-25	35,800	$17.22	402,861	No	4	S	Direct
Common Stock	Acquisiton	2011-02-28	15,000	$10.11	417,861	No	4	M	Direct
Commom Stock	Disposition	2011-02-28	15,000	$17.32	402,861	No	4	S	Direct
Common Stock	Acquisiton	2011-02-28	1,053	$10.08	403,914	No	4	J	Direct
Common Stock	Disposition	2011-02-28	19,900	$17.28	384,014	No	4	S	Direct
Common Stock	Disposition	2011-03-01	44,300	$16.83	339,714	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	J	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option (right to buy)	Disposition	2011-02-28	15,000	$10.11	15,000	$10.11

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2011-02-28	2011-12-11	No	4	M	Direct

Footnotes

Represents a planned sale by Dr. Meanwell during an available trading window.
The range of prices for the transactions reported on this line is between $17.06 and $17.31 per share. The price reported above reflects the weighted average sales price. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Represents the exercise and sale of options that were set to expire in December 2011.
The range of prices for the transactions reported on this line is between $17.17 and $17.53 per share. The price reported above reflects the weighted average sales price. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
Acquired under The Medicines Company employee stock purchase plan on 02/28/2011.
The range of prices for the transactions reported on this line is between $17.16 and $17.38 per share. The price reported above reflects the weighted average sales price. The reporting person undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The range of prices for the transactions reported on this line is between $16.52 and $17.38 per share. The price reported above reflects the weighted average sales price. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
As of 03/1/2011, the original grant (15,000 granted on 12/11/2001) was fully vested.